Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Moodys
Baxter
McKinsey
McKesson

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Alvimopan - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for alvimopan and what is the scope of patent protection?

Alvimopan is the generic ingredient in one branded drug marketed by Cubist Pharms and is included in one NDA. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Alvimopan has twenty patent family members in fourteen countries.

There are four drug master file entries for alvimopan. One supplier is listed for this compound.

Recent Clinical Trials for alvimopan

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, San DiegoPhase 2
Hadassah Medical OrganizationPhase 2
University of Puerto RicoPhase 4

See all alvimopan clinical trials

Recent Litigation for alvimopan

Identify potential future generic entrants

District Court Litigation
Case NameDate
MERCK SHARP & DOHME CORP. v. TEVA PHARMACEUTICALS USA, INC.2017-09-08
CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD.2017-09-06

See all alvimopan litigation

Pharmacology for alvimopan
Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Synonyms for alvimopan
[[(S)-2-Benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propionyl]amino]acetic acid
053A893
145590-44-9
156053-89-3
170098-38-1 (dihydrate)
2-((S)-2-benzyl-3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanamido)acetic acid
2-[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanamido]acetic acid
2-[[(2S)-2-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl]-3-phenylpropanoyl]amino]acetic acid
2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid
A11881
AC1NUQN6
ACN-047960
Adl 8-2698
AJ-45653
AK119795
AKOS015896476
Alvimopan [INN]
Alvimopan anhydrous
Alvimopan, >=98% (HPLC)
anhydrous alvimopan
API0025949
AS-35088
AX8245211
BDBM50088381
C25H32N2O4
CHEBI:135686
CHEMBL270190
CS-0536
CTK8F0805
DB06274
DTXSID60166035
Entereg
FT-0652843
Glycine, N-((2S)-2-(((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-1-oxo-3-phenylpropyl)-
GTPL7471
HSDB 7704
HY-13243
I06-1921
LY 246736
LY246736
MolPort-006-167-841
NCGC00378640-02
Q153V49P3Z
RTX-013338
S036
SCHEMBL49578
SR-01000945029
SR-01000945029-1
ST24039017
ST24045942
trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine
UNII-Q153V49P3Z
W-5416
ZINC3802417

US Patents and Regulatory Information for alvimopan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
AstraZeneca
Dow
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.